Patents by Inventor Eric Swift

Eric Swift has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11974980
    Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.
    Type: Grant
    Filed: June 10, 2021
    Date of Patent: May 7, 2024
    Assignees: Provectus Pharmatech, Inc., UTI Limited Partnership
    Inventors: Jamie Singer, Eric A. Wachter, Satbir Thakur, Lucy Swift, Chunfen Zhang, Mohit Jain, Aru Narendran
  • Publication number: 20240082206
    Abstract: A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.
    Type: Application
    Filed: August 18, 2022
    Publication date: March 14, 2024
    Applicants: Provectus Pharmatech, Inc., UTI Limited Partnership
    Inventors: Eric A. Wachter, Dominic Rodrigues, Satbir Thakur, Lucy Swift, Chunfen Zhang, Mohit Jain, Aru Narendran
  • Patent number: 5145182
    Abstract: A board type game which utilizes lasers where players selectively divert the path of laser beams. The board apparatus comprises an enclosed chamber formed by a top and bottom piece and a frame piece within which laser beams are directed down symbolic rows and columns constituting a matrix of squares. Each square has an X-shaped slot along the diagonals of the square. These slots are formed in the bottom piece and top piece. Deflecting pieces, which may be mirrors, are placed at the player's discretion in diagonal slots of an X-shaped to deflect an incident laser beam from a row or column to a corresponding column or row. A scoring module, sensitive to incident laser light, is positioned in the chamber in front of each player. The players alternate in placing deflecting pieces in the chamber with the object to either direct their laser beams toward the opponent's scoring module or to prevent their opponent's laser beams from reaching their own scoring module.
    Type: Grant
    Filed: November 15, 1990
    Date of Patent: September 8, 1992
    Assignee: Entercon Technologies, Inc.
    Inventors: Philip Swift, Eric Swift, Terrence L. Glatt